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Abstract
Background: Drop-out is an important problem in the treatment of substance use disorder. The focus of this
study was to investigate the effectiveness of within treatment assessment with feedback directly to patients with
multiple substance use disorder on outpatient individual treatment adherence. Feedback consisted of personal
resources’ and readiness to change status and progress that facilitate or hinder change, thereby using graphical
representation.
Methods: Informed consent was obtained from both the control and experimental groups to be involved in
research and follow-up. Following Zelen’s single consent design, baseline participants (n = 280) were randomised
(sample-size-estimation: 80%power, p=.05, 2-sided) and treatment consent was obtained from those allocated to
the experiment (n = 142). In both groups, equal numbers of patients did not attend sessions after allocation. So,
227 persons were analyzed according to intention-to-treat analysis (ITT: experiment n = 116;control n = 111).
Excluding refusals 211 participants remained for per-protocol analysis (PP: experiment n = 100; control n = 111),
The study was conducted in five outpatient treatment-centres of a large network (De Sleutel) in Belgium.
Participants were people with multiple substance use disorder -abuse and dependence- who had asked for
treatment and who had been advised to start individual treatment after a standardised admission assessment with
the European Addiction Severity Index.
The experimental condition consisted of informing the patient about the intervention and of subsequent
assessments plus feedback following a protocol within the first seven sessions. Assessments were made with the
Readiness to Change Questionnaire and the Personal Resources Diagnostic System. The control group received the
usual treatment without within treatment assessment with feedback. The most important outcome measure in this
analysis of the study was the level of adherence to treatment at and beyond eight sessions.
Results: Individual treatment that included assessment with feedback increased adherence to treatment at and
beyond eight sessions (RR = 1.6,95%CI:1.2-2.2). Benefit was also found at and beyond twelve sessions, which was
the number of sessions required to complete 90% of the assessments with feedback in practice (RR = 1.6,95%
CI:1.2-2.5).
Conclusions: Assessment with feedback in routine practice improved adherence to treatment. More research is
needed to evaluate progress in social functioning and motivation to change in outpatient treatment of substance
use disorder, thereby using objective measures
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Drop-out is an important problem in the treatment of
people with multiple substance use disorder. There is
growing agreement for substance abuse and dependence,
being a chronic and relapsing condition [1-3]. The effec-
tiveness of treatment to stabilize or overcome a chronic
condition is strongly related to treatment compliance
[3]. Among alcohol-dependent people, diabetics or per-
sons with hypertension it is common to find a compli-
ance rate below 50% [4].
In a therapeutic community environment for drug
addicted people, evidence has been found that family-
[5,6], social network- [7,8], and staff-involvement [9,10],
improve retention levels. In the broader area of health
care, patient-based measures in routine practice com-
bined with feedback were found to improve significantly
the process and outcome of patient care [11]. In mental
healthcare, feedback to clinicians about patients’ pro-
gress based on routine outcome monitoring affected
outcome and even the number of sessions in psychologi-
cal interventions [12,13].
In the realm of outpatient treatment of substance use
disorder, compliance is also associated with session
attendance a/o adherence to treatment. Regular treat-
ment often relies on assessment, but outside its use in
planning, monitoring, and evaluating interventions,
assessment and feedback as part of the treatment itself
and its positive effect on patient adherence is under-
investigated. Kypri et al. focused on this issue, related to
contamination of clinical trials [14], and found that rou-
tine screening and minimal assessment themselves may
p r o d u c es o m eb e n e f i t[ 1 5 ] .I nl i n ew i t ht h es t u d i e s
based on routine outcome monitoring in psychotherapy
[12,16], Hawkins et al. [17] developed a similar approach
in the treatment of substance use disorder. Their focus
was on feedback to clinicians about lack of progress in
order to reduce the risk of patient drop-out.
In this study, assessment and feedback is introduced
as part of the treatment process itself. It is aimed to
offer opportunities to support counselling by establish-
ing a collaborative relationship and a patient-centred
focus [18,19]. This therapeutic method of assessment
[20] seeks to integrate key features of therapeutic alli-
ance between clinician and patient in assessment and
feedback sessions. Feedback is given to the patient each
time at the next session after assessment. It consists of
communicating the status of substance use, readiness to
change, and personal resources that may facilitate or
hinder change. Repeated assessment and graphical
representation is considered to provide opportunities for
feeding back of progress, treatment recommendation,
and further action. It is also providing the patient with
new ways of thinking and feelings about self and others.
This study addresses the question whether continuing
rounds of assessment with personal feedback to patients
that replace a number of regular outpatient sessions in
the treatment of people with multiple substance use dis-
order, improves adherence, compared to an outpatient
approach without such within treatment assessment and
feedback. It is the most important aim of this study to
investigate the effectiveness of within treatment assess-
ment and personal feedback to patients on outpatients’
adherence to treatment. The reporting follows the
CONSORT-guidelines [21-23].
Method
Study Design
In an attempt to determine whether enhanced adher-
ence could be demonstrated by the introduction of
within treatment assessment and personal feedback in
outpatient treatment of substance use disorder, we set
up an experimental study. This study was a multi-centre
randomised controlled trial registered in the ISRCTN-
database (ISRCTN65456186). It was embedded within
an already existing system to ask informed consent to
all patients for the use of admission assessment and
treatment data for research purposes, and for follow-up.
To minimize problems associated with the clinicians’
resistance to enter patients into a clinical trial, Zelen’s
single consent design was chosen [24-26]. The key char-
acteristic of this method is that participants were rando-
mised and treatment consent was obtained from
participants who were allocated to the experimental
intervention, while controls did not receive the experi-
mental treatment but get the best usual care. In such an
open trial, statistical power can be affected by a high
proportion of participants getting usual care. Therefore,
Adamson et al. [27] advised performing sample-size-esti-
mation before the start of the project and an intention-
to-treat analysis.
Setting and Participants
All persons who entered one of the five outpatient drug-
treatment centres of the treatment network ‘De Sleutel’
in Belgium between March 2007 and March 2009 were
candidates for inclusion in the study. Based upon yearly
reports, patient characteristics in the five centres were
assumed to be very comparable. To be taken in charge
for treatment in one of these centres, patients should be
diagnosed DSM IV substance abuse or dependence for
at least one substance, exclusive single alcohol abuse or
dependence. The inclusion criteria for the trial were
that the patient: (1) gave informed consent about the
use of data and being contacted for follow-up, (2) suffi-
ciently understood the Dutch language, (3) passed the
full admission assessment, consisting of at least a first
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session, and (4) was advised to start individual treat-
ment. The study was approved by the Central Ethics
Board for the Mental Health Sector of the n.p.o. Provin-
cialat of the Brothers of Charity (ref. OG054-2006-19).
Assessment instruments
EuropASI and feedback form
Admission assessment was based upon the European
version of the Addiction Severity Index (EuropASI) [28].
The Dutch version of EuropASI (Cronbach’sa l p h a s>
=.70, except for employment status) [29], adapted for
Flanders, was used. This semi-structured interview offers
an inventory of problems in seven potential problem
areas (physical health, education-work-income, alcohol
use, drug use, judicial, relations, psycho-emotional). The
information from ASI is synthesized on a two-sided
feedback form, placing positive aspects of the patient’s
experience against the problems in each life area. The
feedback form helps clinicians to communicate findings
from EuropASI with the patient and to suggest and sup-
port treatment options [30].
Readiness to Change Questionnaire (RCQ)
The RCQ was used for within treatment assessment and
feedback. Originally, the RCQ was a self-rating question-
naire [31] used to assess the first three stages of change,
which are pre-contemplation, contemplation and action.
The Dutch version of this instrument [32] has been
adapted for poly-drug abusers. For each substance sepa-
rately, being in action could be distinguished from not
being in action (Cronbach’s alphas > = .70, except for pre-
contemplation) [33]. Feedback was based on the principles
from the trans-theoretic model approach. For each sub-
stance that was used in the last 30 days, the clinician com-
mented on whether the person was in pre-, contemplation
or in action. The information about stage of change was
further elaborated, making use of the number and type of
used substances, and the number of use-days.
Personal Resources Diagnostic system (PREDI)
Two scales were used within treatment from PREDI
[34], originally a German instrument consisting of three
scales: personal resources and wish to change. The per-
sonal resources scale provided the appreciation of both
the clinician and the patient, the wish to change scale
only the patient’sa p p r e c i a t i o ni n1 6i m p o r t a n tl i f e -
areas, which were: every day life situation, living situa-
tion, financial situation, legal situation, work situation,
health status, health behaviour, substance use, self-
esteem, self-realization, self-control, contact with reality,
partner relation, family relations, social relations, social
cultural situation. It was translated into Dutch, using
common rules for cross-cultural adaptations of health
measurements [35]. Preliminary to this study, the system
was validated in a small sample of patients with
substance use disorder (personal resources’ Cronbach’s
alpha=.81; wish to change’s Cronbach’s alpha=.83) [36].
Feedback consisted of the synthesis of a patient’sp a r t i -
cular personal resources and a focus on the life areas
where the person clearly indicated a wish to change.
Study interventions
The trial was presented in the centres during the first
quarter of 2007. Clinicians were mainly social, educational,
and/or psychological workers or psycho-therapists. Their
basic training was completed with EuropASI-assessment
and feedback, and with motivational interviewing. They
had at least one year of training or experience. Inspired by
Del Boca & Darkes’ guidelines [37] for enhancing validity
and utility of randomised controlled trials, a manual was
devised that included a training DVD for the experimental
sessions. Extra training for supplementary assessment
(RCQ and PREDI) with feedback took place in the centres
between April and June 2007.
The admission assessment was similar in all centres
for all patients. This study focused on the individual
treatment after admission, where the treatment length
usually was open-ended. Regular treatment consisted of
non-manualized individual counselling sessions of about
one hour, principally aimed at changes in drug-use
behaviour. The expected treatment duration, number or
intensity of counselling sessions were defined only by
the clinicians’ subjective judgment about progress
towards goals and life changes, although such progress
was not measured objectively.
In the experiment, continued assessment and feedback
sessions according to the manual, replaced the regular
treatment sessions (Table 1). The therapists themselves
administered the assessments and/or gave feedback
within the one-hour-sessions instead.
Unlike those in the control group, people in the
experimental group were informed in the first session
about further sessions dealing with continued assess-
ment and feedback and asked for consent. During ses-
sion three (Table 1), the clinician provided the patient
with feedback on RCQ using the trans-theoretic model,
graphical representation of change and worksheets [38].
For feedback on PREDI a standardised form was used
that showed a time-schedule and the personal resources
on which to focus further actions. Planning for repeated
measurement with feedback using the same instruments
was left to the clinicians, with about 30 days in between
as a guideline. The researcher closely followed up the
clinicians’ adherence to the manual.
Outcome measure
D a t a - c o l l e c t i o no np a t i e n t s ’ attendance at counselling
sessions was part of the routine-administration in the
central database of the De Sleutel-network. The start
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end of the whole treatment was also documented, but
the most important outcome measure in this study was
the adherence to individual counselling treatment.
Adherence was measured by counting the total number
of sessions between the date of the first session after
admission and the last session date. Therefore, the initial
assessment sessions being part of the admission assess-
ment did not count towards sessions in the outcome
measure. Since the first five trial related assessment and
feedback sessions in the experimental group take
approximately seven sessions (Table 1), completing at
least eight individual counselling sessions after admis-
sion was set as a first outcome measure. In reality, how-
ever, 90% of the assessment and feedback activities took
place within the first twelve sessions, so completion of
at least twelve sessions was set as a second outcome
measure.
Sample size and power
Sample size estimation was based upon the results of a
study on retention in treatment, retrieved from the cen-
tral database of the De Sleutel-network during the per-
iod from 1999 to 2006. The usual course of treatment
took six months for 80% of the patients during that per-
iod, with a mean of 5.9 sessions (± 3.5). 56% of patients
had fewer than five sessions, 18.3% had eight or more
sessions. Based upon 80% power to detect statistically
significant differences (p=.05;two-sided), a sample size of
at least 100 patients in each study arm was required to
demonstrate doubling of the number of patients attend-
ing eight or more sessions. While power calculations
yield the number of subjects needed at the end of fol-
low-up, we aimed at selecting more subjects (n = 320)
and accounted for likely drop-out [39] (Figure 1).
Randomisation and enrolment
The researcher distributed five closed envelopes to each
outpatient centre each month - two experimental/three
controls or three experimental/two controls. Each of the
closed envelopes was assigned to an eligible patient by
the clinical supervisor, and only after the assignment was
made the envelope was opened to determine whether the
patient was assigned to the control group or the experi-
mental group. The researcher evaluated monthly the
enrolment process and confirmed whether the patients
assigned met or did not meet all eligibility criteria.
320 patients were assessed for eligibility, of which 40
were excluded because they did not meet the inclusion
criteria, so at baseline 280 persons were randomly
assigned to the experimental group (n = 142) and to the
control group (n = 138) (Figure 1). 26 eligible patients
assigned to the experimental group and 27 patients
assigned to the control group and being referred to indi-
vidual treatment did not attend any sessions after
admission assessment. They were excluded from further
analyses. Thus, the intention-to-treat analysis is based
on 116 patients in the experimental group and 111
patients in the control group. Of them who attended
their first individual counselling session, 16 patients in
the experimental group refused participation and were
excluded for per-protocol analysis.
Statistical Analysis
The Pearson Chi-square test and the independent sam-
ples T-test were used to test for differences in patient
characteristics between both allocations at baseline. A p-
value of .05 or less was considered to indicate statistical
significance. The outcome measure was adherence to
treatment at and beyond eight and twelve sessions. Risk-
ratios (RR) with accompanying 95% confidence intervals
were calculated to evaluate adherence to the individual
treatment that included psychological assessment and
feedback. In this study, the word “risk” referred to a
desired effect. Risk ratios of 1 indicate a null-finding,
while 95% confidence intervals (CI) should not include
1 to be statistically significant. Risk ratios > 1 are indi-
cating enhanced likelihood of the desired effect. All ana-
lyses were performed using SPSS for Windows (release
16.0).
Table 1 Scheduling of planned assessment and feedback
sessions
session
number
experimental group planned
assessment and feedback
control
group
1 information plus consent
First Readiness to Change Questionnaire
(RCQ)
Regular
session
2 First RCQ (1) Regular
session
3 Feedback on first RCQ Regular
session
4 Regular session Regular
session
5 Personal Resources Diagnostic system
(PREDI), part one
Regular
session
6 PREDI, part two Regular
session
7 Feedback on PREDI Regular
session
8 Regular session Regular
session
9 Second RCQ (± 30 days after first RCQ) Regular
session
10 Feedback on second RCQ Regular
session
11 Regular session Regular
session
12 ... ...
(1) in some cases the First RCQ was completed at the same session where
informed consent was given, in other cases at the next session.
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Baseline characteristics by allocation
To exclude for bias, the characteristics at baseline of
patients allocated to the experimental group are com-
pared with those of the control group (Figure 1, first
split). Table 2 shows several patient characteristics in
both groups. All data were retrieved from EuropASI. No
statistically significant differences were found between
the groups (p < .05), except for problem-severity con-
cerning work and substance-abuse. In the control group,
more patients had severity indexes for work above four
and a bit smaller average substance-abuse severity index
Randomized (n=280) 
Assessed for eligibility 
(n=320) 
Allocated to Treatment-as-usual 
(n=138) 
Received treatment-as-usual 
(n=111) 
Did not present anymore after 
allocation (n= 27) 
Allocated to Intervention (n=142) 
Received intervention (n=116) 
Did not present anymore after 
allocation(n=26) 
Excluded (n=40) 
Did not meet inclusion 
criteria:  
 EuropASI missing 
(n=4) 
 Language problem 
(n=2) 
 Group treatment a/o 
medical treatment 
(n=31) 
 Refused use of baseline 
data and follow-up 
contact (n=3)
Start Treatment-as-usual (n=111)  Start Intervention (n=116) 
- refused intervention (n=16) 
Analyzed (n=111)  Analyzed (n=116) 
Analyzed (n=111)  Analyzed (n=100) 
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Figure 1 Flow-chart of patient-acceptance process for the trial.
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Experimental (n = 142) Control (n = 138) Pearson Chi
2 or T-value P
Mean age ± SD,y 27.4 ± 7.1 26.9 ± 6.6 .59 .55 n.s.
Men, n (%) 120 (84.5) 108 (78.3) 1.8 .22 n.s.
Country of birth, n (%)
Belgium 131 (92.3) 134 (97.1) 8.3 .49 n.s.
Other 11 (7.7) 4 (2.9)
Relationship, n (%)
Never been Married 119 (83.8) 111 (80.4) 3.6 .61 n.s.
Living situation, n(%)
Partner & children 19 (13.4) 18 (13.0) 9.6 .30 n.s.
Partner no children 23 (16.2) 31 (22.5)
With parents 45 (31.7) 37 (26.8)
Alone 35 (24.6) 29 (21.0)
Educational level, n (%)
< = vocational until 2nd degree 58 (42.6) 56 (42.1) 7.2 .62 n.s.
Vocational & 3rd or 4th degree 37 (26.1) 30 (21.7)
Technical secondary 24 (16.9) 20 (14.5)
General Secondary 8 (5.6) 12 (8.7)
Employment status, n (%)
Employed full-time or part-time 94 (68.1) 90 (65.2) 8.8 .26 n.s.
Profession, n(%)
Unschooled labour 71 (50.0) 52 (37.7) 7.5 .28 n.s.
Schooled labour 41 (28.9) 45 (32.6)
Other or missing 30 (21.1) 41 (29.7)
Primary substance, n (%)
Amphetamines 17 (12.0) 12 (8.7) 17.4 .19 n.s.
Cannabis 38 (26.8) 51 (37.0)
Cocaine 30 (21.1) 19 (13.7)
Opiates 30 (21.1) 19 (13.8)
Mean years of drug use ± SD
Amphetamines 4.6 ± 5.0 3.3 ± 3.1 1.8 .07 n.s.
Cannabis 8.0 ± 5.8 7.9 ± 5.4 .91 .84 n.s.
Cocaine 3.1 ± 3.7 3.1 ± 3.7 -.10 .92 n.s.
Opiates 3.8 ± 4.1 3.0 ± 2.3 1.0 .30 n.s.
Mean n of drugs ever used ± SD 3.9 ± 2.0 3.7 ± 1.9 .98 .38 n.s.
Mean n of treatments drugs ± SD 1.0 ± 1.3 0.9 ± 1.3 .64 .52 n.s.
EASI-severity > = 4, n (%)
Physical health 20 (14.4) 21 (15.3) 4.4 .82 n.s.
Education, Work, Income 38 (28.0) 45 (33.9) 17.0 .02 < .05
Alcohol use 33 (23.4) 35 (25.2) 6.5 .60 n.s.
Drug use 135 (89.5) 122 (88.4) 10.6 .06 n.s.
Judicial 35 (25.0) 43 (11.8) 11.8 .11 n.s.
Relations 78 (56.5) 72 (52.5) 6.6 .47 n.s.
Psycho-emotional 71 (51.4) 72 (52.5) 2.0 .96 n.s.
Mean EASI Severity Indexes ± SD
Physical health 2.0 ± 1.6 1.9 ± 1.6 .34 .73 n.s.
Education, Work, Income 2.5 ± 1.5 2.5 ± 1.8 .13 .90 n.s.
Alcohol 2.3 ± 1.7 2.2 ± 1.9 .47 .64 n.s.
Drugs 5.0 ± 1.1 4.6 ± 1.1 3.1 .002 < .05
Legal 2.4 ± 1.7 2.4 ± 2.0 -.09 .93 n.s.
Family 3.8 ± 1.5 3.6 ± 1.6 .85 .40 n.s.
Psycho-emotional 3.5 ± 1.8 3.4 ± 1.9 .76 .90 n.s.
EASI: EuropASI; n.s.: not significant; EASI-severity > = 4 means that treatment is needed [46].
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participants were mainly never-married male Belgians
with an average age of 27. Most patients lived with par-
ents or alone. Their schooling degree was low with less
than 10% who finished secondary school. About two-
thirds were employed full-time or part-time. Cannabis
was the primary substance of abuse, followed by
cocaine, opiates, and amphetamines. For almost half of
the study group, the treatment was their first treatment
for drugs/substance abuse. Higher problem severity was
m o s tf r e q u e n ti nt h ea r e ao fd r u ga b u s e ,f o l l o w e db y
family and social relationships and psycho-emotional
issues. No statistically significant difference between the
two groups was found in the number of persons that
did not present anymore after allocation (Figure 1).
These individuals - respectively 27 and 26 persons in
the control and the experimental group - were not
included in further analyses.
Adherence to treatment
The primary outcome measure for this study was treat-
ment adherence at and beyond eight sessions. The
results confirmed enhanced likelihood of this desired
effect in patients allocated to the experimental
condition.
Table 3 showed that adherence to treatment at and
beyond eight sessions improved statistically significant
in individual treatment where assessment and feedback
was given (RR = 1.6,95%CI:1.2-2.1 in intention-to-treat
(n = 227) or RR = 1.6,95%CI:1.2-2.2 in per-protocol (n
= 211)). It means that 60% more persons adhered to
individual treatment for at least eight sessions if contin-
ued assessment and feedback was provided within the
individual treatment sessions, compared to those who
received regular sessions. This result was found in both
intention-to-treat and per-protocol analysis.
A second outcome measure was also set for adherence
to treatment at and beyond twelve sessions. Yet, 90% of
the assessment and feedback sessions (Table 1) took
place within the first twelve sessions. In intention-to-
treat analysis, the results showed again statistically sig-
nificant improved adherence at and beyond twelve ses-
sions, where continued assessment and feedback took
place (RR = 1.6, 95%CI:1.0-2.5, n = 227). In per-protocol
analysis, the results even showed 70% more persons that
adhered to individual treatment for at least twelve ses-
sions (RR = 1.7, 95%CI:1.1-2.7, n = 211).
Discussion
Adherence in addiction treatment and studies is an impor-
tant issue [40]. The results indicate that counselling ses-
sions which included assessment with feedback directly to
patients increased adherence to outpatient session-based
treatment of substance use disorder, compared to an
approach without assessment with feedback. Our results
can be compared with findings in general health care [11]
and in psychotherapy [41], although not 1:1. The nature of
this trial was different in several aspects: (1) structuring
treatment and continuing assessment was part of the
intervention itself; (2) the trial - a non-medical interven-
tion - was conducted in a population with multiple sub-
stance use disorder, where drop-out with low adherence
and attendance rates are common [42], and (3) the design
provided the inclusion of experienced therapists them-
selves to realise the intervention.
As a consequence, this study had limitations. Con-
ducting a well-structured randomized controlled trial in
a natural setting, where no manuals or protocols are
used, does limit the conditions in the control group,
because of possible contamination [15,14]. To keep the
design pure, further structuring and assessments in the
control group were not designated. Therefore, the pri-
mary outcome measure was limited to adherence at and
beyond eight sessions and no other outcome measures
were included. Studies in psychotherapy have found that
25% of patients reach clinically significant change in
subjective discomfort, interpersonal relationships and
social role functioning after five sessions, 50% reach
clinically significant change after nine sessions, and 75%
do so after 17 sessions [43]. In this study, most of the
benefit was expected next to the first seven sessions,
during which patients in the experiment were exposed
to the assessment with feedback sessions. Application of
a cut-point at twelve sessions also showed significant
differences between the control group and the experi-
mental group.
The strengths of this trial included its being built
upon an already existing monitoring system, the use of
well evaluated instruments and that it is associated with
the real-world context where the intervention took
place. Other than establishing protocols and providing a
manual and continued training and supervision, the
researcher had no influence on common processes in
Table 3 Adherence at and beyond eight and twelve
sessions in intention-to-treat and per-protocol analysis
> = 8 sessions > = 12 sessions
Intention-to-treat (n = 227)
experimental 53.4% 33.6%
control 34.2% 20.7%
Risk ratio (RR) 1.6 1.6
95%CI 1.2-2.1 1.0-2.5
Per-protocol (n = 211)
experimental 56.0% 36.0%
control 34.2% 20.7%
Risk ratio (RR) 1.6 1.7
95%CI 1.2-2.2 1.1-2.7
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on the unpredictable behaviour of patients. In all likeli-
hood, the realised randomization and the participation
level in a natural setting was the highest that could be
reached in a trial where the trial’s focus itself could lead
to an increased workload without the benefit of addi-
tional clinical staff [40]. Moreover, the intervention took
place within a real clinician-patient relationship, where
good communication should consist of both instrumen-
tal (here, the trial intervention), and affective behaviours.
Both elements, although unfavourable to meeting the
internal validity benchmark, certainly enhanced external
validity, and thus contributed to contextual evidence,
favouring the probability of adoption in clinical settings
[ 4 4 , 4 5 ] .T h er e s u l t sm a ya l s oh a v es i g n i f i c a n c ei nt h e
broader area of health care, where low compliance rates
a r eo fc o n c e r ni nc a s eo fp r e v e n t i v ea d v i c ea n d / o r
chronic conditions to cope with.
Conclusion
The use of assessment instruments with feedback
directly to patients provided evidence to enhance adher-
ence in routine practice in the treatment of substance
use disorder. This finding may inspire the broader field
of health care, especially in the care of chronic condi-
tions and mental health to further elaborate continued
measurement and outcome-feedback in daily practice.
More research is needed to evaluate progress in social
functioning and motivation to change in the treatment
of substance use disorder, thereby using objective
measures.
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